Ipamorelin and CJC-1295 Stack: Complete Guide to Dosing, Benefits, and Research

If you've spent any time researching peptide therapy or growth hormone optimization, you've almost certainly come across the Ipamorelin and CJC-1295 stack. It's one of the most widely used peptide combinations in clinical longevity practices, fitness medicine, and research settings — and for good reason. The synergy between these two compounds produces substantially larger, cleaner growth hormone (GH) pulses than either peptide achieves alone, while preserving the pulsatile GH release pattern that mirrors healthy physiology.

This guide covers everything you need to know: how each peptide works, why they work better together, optimal dosing protocols, realistic benefits and side effects, the important distinction between CJC-1295 with and without DAC, and the complex regulatory landscape as of 2026.

Important legal notice: Neither ipamorelin nor CJC-1295 is approved by the FDA for human use. Both are research chemicals. This article is for educational purposes only and does not constitute medical advice. Always consult a qualified physician before using any peptide compound.

What Is Ipamorelin?

Ipamorelin is a synthetic pentapeptide classified as a growth hormone-releasing peptide (GHRP) and ghrelin mimetic. Originally developed by Novo Nordisk in the late 1990s, it remains the most selective GHRP ever characterized — a distinction that directly explains its popularity in stacking protocols.

Mechanism of Action

Ipamorelin works by activating the growth hormone secretagogue receptor (GHS-R1a) on pituitary somatotroph cells — the same receptor targeted by ghrelin, your body's endogenous hunger and GH-signaling hormone. This receptor activation does two things simultaneously:

• It suppresses somatostatin, the inhibitory signal that otherwise dampens GH release
• It directly triggers a rapid GH secretion pulse from the pituitary via intracellular calcium mobilization

The result is a discrete, short-duration GH pulse that closely mirrors the body's natural GH pulsatility.

Why Ipamorelin's Selectivity Matters

The landmark 1999 study by Raun et al. in the European Journal of Endocrinology (PMID: 9849822) established that ipamorelin does not elevate ACTH or cortisol, even at doses more than 200-fold above the GH-effective ED50. It showed no effect on FSH, LH, prolactin, or TSH. This stands in sharp contrast to older GHRPs like GHRP-6 and GHRP-2, which co-release cortisol and ACTH — exactly what you don't want when the goal is clean growth hormone optimization.

The paper concluded that ipamorelin is "the first GHRP-receptor agonist with a selectivity for GH release similar to that displayed by GHRH." This is why ipamorelin is the preferred GHRP partner for stacking — it delivers the GH stimulus without the unwanted hormonal baggage.

What Is CJC-1295?

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) — the endogenous hypothalamic peptide that instructs the pituitary to produce and release GH. It's a 30-amino acid peptide engineered with strategic amino acid substitutions that eliminate the DPP-4 cleavage sites that rapidly degrade native GHRH, which has a plasma half-life of only approximately 7 minutes.

CJC-1295 With DAC vs. Without DAC: A Critical Distinction

There are two distinct versions of CJC-1295, and confusing them is one of the most common mistakes in peptide stacking:

• CJC-1295 without DAC (also called Modified GRF 1-29 or Mod-GRF 1-29): Half-life of 30 minutes to 2 hours. Produces discrete, pulsatile GH bursts. Preferred for stacking with ipamorelin.
• CJC-1295 with DAC: Half-life of 6–8 days, achieved by covalent binding to albumin via a maleimide group. Produces sustained, chronic GH elevation. Incompatible with ipamorelin stacking goals.

When stacking with ipamorelin, always use CJC-1295 without DAC. The DAC version's dramatically extended half-life destroys the synchronized pulsatile GH release that makes this stack effective, increases side effects, and elevates receptor desensitization risk.

Why Stack Ipamorelin With CJC-1295?

The combination is one of the most elegant examples of dual receptor synergy in peptide pharmacology.

Two Independent Pathways, One Amplified Result

CJC-1295 and ipamorelin act through entirely different receptor systems that converge on the same pituitary somatotroph cells:

• CJC-1295 (GHRH pathway): Stimulates adenylyl cyclase, cAMP, PKA signaling cascade leading to GH synthesis and release
• Ipamorelin (GHRP/ghrelin pathway): Mobilizes intracellular calcium via phospholipase C, triggering GH vesicle exocytosis

When both signals arrive simultaneously at the somatotroph, the GH pulse is substantially larger than either compound produces alone. Research protocols consistently describe a 3 to 5x amplification of the GH pulse compared to GHRH stimulation alone. Put simply: CJC-1295 tells the pituitary to make and release GH; ipamorelin removes the brakes and triggers the release.

Ipamorelin's suppression of somatostatin — the GH-inhibitory signal — further amplifies this effect, making the combined pulse both larger and more consistent. Since both CJC-1295 no-DAC and ipamorelin have similar half-lives of approximately 30 minutes to 2 hours, they peak and clear together, preserving the natural on/off pulsatile pattern that is physiologically appropriate for GH signaling.

Dosing Protocols

Standard Protocol

The most widely cited clinical approach for the CJC-1295 no-DAC + ipamorelin stack:

• Dose: 200 mcg of each peptide per injection, which can be combined in the same syringe
• Frequency: Once daily, 5 days on and 2 days off
• Timing: Bedtime, minimum 2 to 3 hours after last meal
• Route: Subcutaneous injection into abdomen, upper thigh, or flank
• Cycle length: 8 to 16 weeks on, followed by 4 to 8 weeks off

Titrated Initiation Protocol

For those new to peptide therapy, a gradual titration reduces side effects:

• Weeks 1 to 2: 100 mcg of each, once daily at bedtime
• Weeks 3 to 4: 100 mcg CJC-1295 no-DAC, 150 to 200 mcg ipamorelin
• Weeks 5 to 8: 100 to 150 mcg each, once daily
• Weeks 9 to 12 (optional split): 100 mcg each, twice daily — fasted morning and bedtime

Why Timing and Fasting Matter

Bedtime dosing is optimal because it amplifies the body's largest natural GH pulse, which occurs approximately 60 to 90 minutes after sleep onset during slow-wave sleep. The fasted state is critical: insulin suppresses GH release, so food intake within 2 to 3 hours before injection significantly blunts the GH response. Wait at least 20 minutes after injecting before eating.

Injection Technique

Reconstitute lyophilized peptide with bacteriostatic water containing 0.9% benzyl alcohol by directing the liquid down the vial wall — never directly onto the powder. Gently swirl to dissolve; never shake or vortex. Use 29 to 31 gauge insulin syringes and inject into pinched subcutaneous fat at a 45-degree angle.

Benefits: What the Research and Clinical Evidence Shows

Muscle Growth and Body Composition

Elevated GH and downstream IGF-1 stimulate protein synthesis, enhance nitrogen retention, and support lean tissue anabolism. IGF-1 activates satellite cells (muscle stem cells), supporting both muscle repair and new growth. Clinical longevity practices report 3 to 8 lbs of lean mass gain over 4 to 6 month cycles — less dramatic than anabolic steroids but accompanied by simultaneous fat loss rather than water weight gain.

Fat Loss Through Lipolysis

GH is a potent lipolytic hormone, activating hormone-sensitive lipase in adipocytes to release stored triglycerides as fuel. The stack preferentially targets visceral and subcutaneous fat. Most users report visible fat loss beginning between weeks 5 and 8, with 10 to 20+ lbs of fat loss commonly reported over full 4 to 6 month cycles combined with appropriate diet and exercise.

Sleep Quality

Often the first benefit users notice — typically within 1 to 2 weeks. GHRH activity is known to increase slow-wave deep sleep via direct hypothalamic effects. Improved deep sleep then enhances GH secretion further, creating a positive feedback loop that also supports muscle protein synthesis, immune function, and cognitive recovery.

Injury Recovery and Tissue Repair

GH and IGF-1 upregulate collagen synthesis and support connective tissue repair. The stack is popular among athletes recovering from musculoskeletal injuries and in post-surgical contexts. Accelerated recovery — rather than direct anabolic effects — is often cited as the most practically valuable benefit by clinical users.

Anti-Aging and Longevity Effects

GH declines roughly 14 to 15 percent per decade after age 30, a phenomenon called somatopause. The CJC-1295 plus ipamorelin stack partially compensates for this decline by restoring more youthful GH pulsatility. Associated benefits include improved skin elasticity and collagen density, bone mineral density preservation, enhanced immune function, better cognitive clarity, and improved cardiovascular markers — effects well-established from decades of exogenous HGH research that operate through the same IGF-1 downstream pathways.

Side Effects and Safety Profile

Common, Generally Mild Side Effects

• Water retention (15 to 25% incidence): GH causes mild sodium and water retention, manifesting as puffiness in hands, feet, or face — particularly in weeks 1 to 4. Typically self-resolves as the body adapts.
• Tingling or numbness in extremities (10 to 20%): Caused by fluid retention compressing peripheral nerves — a mild, reversible carpal tunnel-like effect. Resolves with dose reduction or cycle completion. Often indicates GH is genuinely elevated.
• Facial flushing: Brief vasodilation within minutes of injection, lasting 5 to 10 minutes. Benign and common with initial injections.
• Mild increased hunger (10 to 15%): Notably less pronounced with ipamorelin than GHRP-6. Most users describe a modest appetite increase for 20 to 30 minutes post-injection.
• Headache (5 to 10%): Transient, associated with the initial GH surge. Typically resolves after the first 1 to 2 weeks.
• Drowsiness after bedtime injection: Generally considered a feature rather than a side effect given the sleep-enhancement goal.

Clinically Significant Concerns

• Insulin sensitivity reduction: GH is counter-regulatory to insulin. Elevated GH can modestly reduce insulin sensitivity and raise fasting glucose. Blood glucose monitoring is recommended for those with pre-diabetes or metabolic syndrome.
• Thyroid effects: Approximately 6.5% of users in observational data developed hypothyroid-like effects. Baseline and mid-cycle thyroid function testing is recommended.
• Cardiovascular effects: The FDA has flagged cardiovascular adverse events including tachycardia, flushing, and transient hypotension associated with CJC-1295, primarily at higher doses in clinical trial settings.
• Cancer risk: GH and IGF-1 are mitogenic. Standard contraindication for anyone with active or historical cancer, particularly hormone-sensitive cancers.

Absolute contraindications: Active or historical cancer, pituitary tumors, diabetic retinopathy, severe kidney or liver disease, pregnancy, and breastfeeding.

What the Research Actually Says

Ipamorelin has been extensively characterized in preclinical research. The foundational Raun et al. (1998) study in the European Journal of Endocrinology established its potency, selectivity, and clean hormonal profile, earning it the designation as the first selective GHRP. Over 150 PubMed-indexed publications have since examined ipamorelin across contexts including sarcopenia, metabolic disorders, and anti-emetic applications.

CJC-1295 has more robust human clinical data. The landmark Teichman et al. (2006) randomized, placebo-controlled, double-blind study in the Journal of Clinical Endocrinology and Metabolism (PMID: 16352683) found:

• A single injection produced 2 to 10x GH increases lasting 6+ days, with IGF-1 elevated for 9 to 11 days
• Multiple doses kept IGF-1 elevated for up to 28 days with cumulative effect
• The DAC variant had an estimated half-life of 5.8 to 8.1 days
• No serious adverse reactions were reported — described as "safe and relatively well tolerated"

A separate study by Ionescu and Frohman (2006) confirmed that pulsatile GH secretion is preserved during continuous GHRH receptor stimulation by CJC-1295 — demonstrating the compound does not suppress the body's natural GH pulsatile architecture.

Important caveat: there are no published randomized controlled trials specifically studying the CJC-1295 plus ipamorelin combination in humans. The synergistic amplification data is extrapolated from separate mechanistic studies and clinical observational data from longevity practices.

Regulatory Status in 2026

The regulatory landscape for both peptides shifted significantly in late 2024. Neither ipamorelin nor CJC-1295 is FDA-approved for any human therapeutic indication. Both were nominated for inclusion in the FDA's 503A compounding bulks list, but in September 2024 those nominations were voluntarily withdrawn.

The FDA's Pharmacy Compounding Advisory Committee subsequently reviewed both compounds and recommended against including either on the compounding bulks list, citing inadequate safety data, cardiovascular adverse event signals, impurity concerns, and immunogenicity risks.

As of 2026, both compounds occupy a regulatory gray zone: not FDA-approved, not legally compoundable in the US, and sold commercially only as research chemicals labeled "not for human use" without FDA oversight of purity, sterility, or potency. Outside the US, they face similar restrictions — prescription-only or controlled in Canada, Australia, the UK, and the EU.

Storage and Handling

• Lyophilized powder: Freeze at -20 degrees Celsius for up to 24 to 36 months. Refrigerate at 2 to 8 degrees Celsius for up to 3 to 6 months. Protect from light and moisture.
• Reconstituted solution: Refrigerate at 2 to 8 degrees Celsius. Stable for up to 28 days in bacteriostatic water. Never freeze reconstituted solutions — freeze-thaw cycles damage peptide structure.
• Always use bacteriostatic water (0.9% benzyl alcohol) for multi-dose vials, not plain sterile water.

Frequently Asked Questions

Can I mix ipamorelin and CJC-1295 no-DAC in the same syringe?

Yes. Both peptides are stable when co-injected in the same subcutaneous injection. Drawing them into the same insulin syringe is standard practice in clinical peptide therapy settings.

Should I use CJC-1295 with or without DAC?

Always use the no-DAC version when stacking with ipamorelin. The DAC version's 6 to 8 day half-life is incompatible with ipamorelin's approximately 2-hour half-life, eliminating the synchronized pulsatile GH release that makes this stack effective.

How long before I see results?

Improved sleep quality is typically the first benefit, often within 1 to 2 weeks. Visible body composition changes begin around weeks 5 to 8. Full effects are most apparent at 3 to 6 months with consistent use combined with appropriate diet and training.

Is this the same as injecting HGH?

No. This stack stimulates your pituitary to produce and release your own GH — it does not introduce exogenous growth hormone. The resulting GH pulses are physiologically patterned and pulsatile, a significant advantage over exogenous HGH. This stack is also considerably less expensive than pharmaceutical HGH.

Conclusion

The ipamorelin + CJC-1295 no-DAC stack represents one of the most pharmacologically coherent peptide combinations for GH optimization. By targeting two independent receptor pathways that converge on pituitary GH release — GHRH receptors via CJC-1295 and GHS-R1a receptors via ipamorelin — the stack produces amplified, pulsatile, selective GH secretion without cortisol co-elevation or hormonal disruption.

The clinical evidence supporting the individual compounds is solid, particularly the human trial data for CJC-1295 and the extraordinary selectivity data for ipamorelin documented in peer-reviewed research. The regulatory landscape is complex and currently unfavorable for compounded preparations in the US, but the underlying pharmacology and clinical rationale remain among the most studied in the peptide secretagogue class.

For anyone considering this stack under physician supervision, the key principles are clear: use CJC-1295 without DAC, dose at bedtime in a fasted state, titrate up gradually, monitor blood glucose and thyroid function, and cycle on/off to preserve receptor sensitivity. Done properly, this stack offers a meaningful, physiologically grounded approach to GH optimization for recovery, body composition, and healthy aging.